GlassScriptPhysician profile
Christina E Oldham
NPI 1154833879
$6,817.68
in general payments reported to CMS, 2019-2025
21 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $748 · 2022: $1,201 · 2023: $1,780 · 2024: $1,786 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,677 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,676.93 |
| Education | $191.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,545.99 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $729.48 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $705.13 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $673.18 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $531.37 | 2021-2025 | |
| Alkermes, INC. | $475.86 | 2021-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $316.53 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $312.56 | 2021-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $238.55 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $229.90 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $225.60 | 2022-2025 | Auvelity |
| Lundbeck LLC | $218.84 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $189.08 | 2021-2024 | Trintellix |
| Indivior INC. | $136.52 | 2021-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $88.79 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $52.11 | 2022-2023 | Azstarys |
| Almatica Pharma LLC | $40.57 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $39.87 | 2023-2024 | Quviviq |
| Janssen Biotech, INC. | $27.53 | 2023 | |
| Ironshore Pharmaceuticals INC. | $21.05 | 2024 | |
| Eisai INC. | $19.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Oldham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.